复星医药公告,控股子公司浙江星浩澎博医药有限公司就XH-S004片启动Ⅱ期临床试验,用于治疗非囊纤维化支气管扩张症。截至2025年4月,XH-S004另一适应症(用于治疗慢性阻塞性肺疾病)于中国境内已获临床试验批准。截至公告日期,XH-S004的累计研发投入约为人民币0.61亿元。
Source Link复星医药公告,控股子公司浙江星浩澎博医药有限公司就XH-S004片启动Ⅱ期临床试验,用于治疗非囊纤维化支气管扩张症。截至2025年4月,XH-S004另一适应症(用于治疗慢性阻塞性肺疾病)于中国境内已获临床试验批准。截至公告日期,XH-S004的累计研发投入约为人民币0.61亿元。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.